The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).
 
Mohammad Jad Moussa
No Relationships to Disclose
 
Alexander Andreev-Drakhlin
Employment - Employee of Genentech, San Francisco, CA
 
Amishi Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Surena Matin
Consulting or Advisory Role - Consulting Fee-FUJIFILM Medical Systems USA, Inc.; Consulting Fee-Janssen Biotech, Inc; Consulting Fee-Johnson & Johnson; Consulting Fee-Merck Sharp & Dohme Corp.
Research Funding - Grant or research support-Helsinn Therapeutics (U.S.) Inc
 
Ana Adriazola
No Relationships to Disclose
 
Leah Shaw
No Relationships to Disclose
 
Marihella Campbell
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Paul Corn
Research Funding - Janssen Oncology (Inst)
 
John Lin
No Relationships to Disclose
 
Sangeeta Goswami
No Relationships to Disclose
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Charles Guo
No Relationships to Disclose
 
Nizar Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Arlene Siefker-Radtke
Consulting or Advisory Role - Scientific advisory board fees from Abbvie, Astellas, AstraZeneca, Basilea, Bicycle Therapeutics, Bristol Myers Squibb, Genentech, G1 Therapeutics, Gilead, Ideeya Biosciences, Immunomedics, Janssen, Loxo, Merck, Mirati, Nektar Therapeutics, Seattle Geneti
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)
 
Matthew Campbell
Honoraria - Axdev; Curio Science; Eisai; Exelixis; MJH Life Sciences; Seagen; Targeted Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; Exelixis; SeaGen